Hilleman Labs establishes Singapore's first pilot manufacturing facility for vaccine development
![](/46/pdcnewsitem/11/55/96/HLN00CPO_Singapore784x590.jpg)
A 30,000-sq. ft cGMP facility and a separate R&D site will work alongside each other to provide end-to end product development solutions for Singapore and low- and middle-income countries
Hilleman Laboratories, a joint venture between Merck & Co and Wellcome Trust, revealed on Monday that it has established Singapore's first pilot vaccine and biologics development and manufacturing hub.
The hub, which was built with the support of the Singapore Economic Development Board (EDB), comprises a cGMP facility at 138 Depot Road and an R&D facility at Biopolis.
The 30,000-sq. ft cGMP facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
The R&D facility at Biopolis, which began operations in April 2021, focuses on early product development of vaccines and biologics, including candidate selection, design, early manufacturing process development and preclinical studies.
This set-up enables the two facilities to work in tandem to provide end-to end product development solutions for Singapore as well as low- and middle-income countries.
EDB's backing will enable Hilleman Laboratories to expand its product development pipeline and harness Singapore’s local network and talent to fast-track the development of novel solutions to tackle the high disease burden of preventable diseases in developing countries.
It will also provide Singapore with capabilities in vaccine and biologics development and manufacturing with an eye on meeting national needs during future pandemics.
Over the next five years, Hilleman Laboratories, which was established in 2009 as an equal joint venture between Merck and Wellcome Trust to develop affordable vaccines and biologics against infectious diseases, is investing almost SGD 80 million ($58 million) in operations, infrastructure and capacity building. The company also plans to hire up to 50 local scientists, engineers, and managers in Singapore.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance